Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 18/3/2019
SIETES contiene 92692 citas

 1 a 20 de 344 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Hengartner MP. What is the threshold for a clinical minimally important drug effect?. BMJ Evidence-Based Medicine 2018;23:21 de noviembre. [Ref.ID 102912]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Furukawa TA, Maruo K, Noma H, Tanaka S, Imai H, Shinohara K, Ikeda K, Yamawaki S, Levine SZ, Goldberg Y, Leucht S, Cipriani A. Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatr Scand 2018;137:junio. [Ref.ID 102911]
3. Cita con resumen
de Boissieu P, Kanagaratnam L, Mahmoudi R, Morel A, Dramé M, Trenque T. Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol 2017;73:517-23. [Ref.ID 101992]
4. Cita con resumen
Aronson J. When I use a word... Safety. BMJ 2015;351:h3521. [Ref.ID 99245]
Greenhalgh T, Maskrey N. Evidence based medicine a movement in crisis?. BMJ 2014;348:g3725. [Ref.ID 98053]
6.Enlace a cita original
Moynihan R, Henry D, Moons KGM. Using evidence to combat overdiagnosis and overtrea tests, and disease definitions in the time of too much. PLOS Medicine 2014;11:e1001655. [Ref.ID 97789]
7.Enlace a cita original
Rawlins MD. Clinical pharmacology in health care, teaching and research. Br J Clin Pharmacol 2013;75:1219-20. [Ref.ID 95328]
8.Enlace a cita original Cita con resumen
Moynihan R. What is disease? And why it's a healthy question. BMJ 2013;346:26. [Ref.ID 94762]
9.Enlace a cita original
Eisenberg DF, Daniel GW, Jones JK, Goehring Jr EL, Wahl PM, Winters P, Levin J, Bohn RL. Validation of a claims-based diagnostic code for Stevens-Johnson syndrome in a commercially insured population. Pharmacoepidemiol Drug Saf 2012;21:760-4. [Ref.ID 93418]
10.Tiene citas relacionadas
Chaisson RE, Nuermberger EL. Confronting multidrug-resistant tuberculosis. N Engl J Med 2012;366:2223-4. [Ref.ID 93175]
11.Tiene citas relacionadas Cita con resumen
Gier MT, Skripoconoka V, Sánchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh W-J, Seaworth B, Geiter LJ, Wells CD. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60. [Ref.ID 93171]
12. Cita con resumen
Aronson JK, Hauben M, Bate A. Defining "surveillance" in drug safety. Drug Saf 2012;35:347-57. [Ref.ID 92783]
13.Enlace a cita original
Llop R, Bosch M, Figueras A, Laporte JR. Separating the wheat from the chaff: essential information in therapeutics. Eur J Clin Pharmacol 2012;68:abril. [Ref.ID 92598]
14. Cita con resumen
Garattini S. Time to revisit the orphan drug law. Eur J Clin Pharmacol 2012;68:113. [Ref.ID 92325]
15. Cita con resumen
Anónimo. Artemisinins in malaria treatment in the UK. Drug Ther Bull 2010;48:129-32. [Ref.ID 89709]
16. Cita con resumen
Anónimo. A guide to health economic evaluations. Drug Ther Bull 2010;48:105-8. [Ref.ID 89279]
17. Cita con resumen
Watts G. Lost without translation?. BMJ 2010;341:428-9. [Ref.ID 89257]
18. Cita con resumen
Anónimo. Rheumatoid arthritis: new guidelines open new doors. Lancet 2010;376:566. [Ref.ID 89165]
19.Tiene citas relacionadas Cita con resumen
Law R. There was also no new subtype. BMJ 2010;341:8. [Ref.ID 88799]
20.Tiene citas relacionadas
Chan M. WHO director-general replies to the BMJ. BMJ 2010;341:7. [Ref.ID 88798]
Seleccionar todas
 1 a 20 de 344 siguiente >>